TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma. Issue 10 (25th February 2021)
- Record Type:
- Journal Article
- Title:
- TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma. Issue 10 (25th February 2021)
- Main Title:
- TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma
- Authors:
- Shang, Mingyi
Weng, Li
Xu, Guifang
Wu, Shaoqiu
Liu, Bingyan
Yin, Xiang
Mao, Aiwu
Zou, Xiaoping
Wang, Zhongmin - Abstract:
- Abstract: Gemcitabine is first‐line chemotherapy for pancreatic cancer, however, the development of resistance limits its effectiveness. The tripartite motif‐containing 11 (TRIM11) protein plays crucial roles in tumor development and undergoes auto‐polyubiquitination to promote interactions in selective autophagy. Therefore, Understanding whether TRIM11 is involved in ferritinophagy and gemcitabine resistance in pancreatic cancer is critical in developing pancreatic cancer therapeutics. TRIM11 expression was validated by Western blot analysis, real‐time polymease chain reaction, and immunohistochemical staining. 3‐(4, 5‐Dimethylthiazol‐2‐yl)‐2, 5‐diphenyltetrazolium bromide and Colony formation assays were performed to investigate pancreatic ductal adenocarcinomas (PDAC) cell viability. Mouse xenograft model of PDAC cells was established to verify the role of TRIM11 in vivo. Coimmunoprecipitation was used to identify the reciprocal regulation between TRIM11 and UBE2N. In this study, we found that TRIM11 expression were higher in PDAC cells and tissues. TRIM11 overexpression promotes PDAC cell proliferation in vitro and tumor growth in vivo. Decreased expression of TRIM11 in PDAC patients is associated with decreased UBE2N and increased TAX1BP1 expression. Coimmunoprecipitation established that TRIM11 interacts and colocalizes with UBE2N. Mechanistically, TRIM11 promoted gemcitabine resistance and suppressed ferritinophagy through UBE2N‐TAX1BP1 signaling. Our findingsAbstract: Gemcitabine is first‐line chemotherapy for pancreatic cancer, however, the development of resistance limits its effectiveness. The tripartite motif‐containing 11 (TRIM11) protein plays crucial roles in tumor development and undergoes auto‐polyubiquitination to promote interactions in selective autophagy. Therefore, Understanding whether TRIM11 is involved in ferritinophagy and gemcitabine resistance in pancreatic cancer is critical in developing pancreatic cancer therapeutics. TRIM11 expression was validated by Western blot analysis, real‐time polymease chain reaction, and immunohistochemical staining. 3‐(4, 5‐Dimethylthiazol‐2‐yl)‐2, 5‐diphenyltetrazolium bromide and Colony formation assays were performed to investigate pancreatic ductal adenocarcinomas (PDAC) cell viability. Mouse xenograft model of PDAC cells was established to verify the role of TRIM11 in vivo. Coimmunoprecipitation was used to identify the reciprocal regulation between TRIM11 and UBE2N. In this study, we found that TRIM11 expression were higher in PDAC cells and tissues. TRIM11 overexpression promotes PDAC cell proliferation in vitro and tumor growth in vivo. Decreased expression of TRIM11 in PDAC patients is associated with decreased UBE2N and increased TAX1BP1 expression. Coimmunoprecipitation established that TRIM11 interacts and colocalizes with UBE2N. Mechanistically, TRIM11 promoted gemcitabine resistance and suppressed ferritinophagy through UBE2N‐TAX1BP1 signaling. Our findings identify TRIM11 as a key regulator of TAX1BP1 signaling with a crucial role in ferritinophagy and gemcitabine resistance in PDAC. Abstract : TRIM11 promoted gemcitabine resistance and suppressed ferritinophagy in pancreatic ductal adenocarcinomas. TRIM11 could regulate TAX1BP1 signaling in a UBE2N‐dependent manner … (more)
- Is Part Of:
- Journal of cellular physiology. Volume 236:Issue 10(2021)
- Journal:
- Journal of cellular physiology
- Issue:
- Volume 236:Issue 10(2021)
- Issue Display:
- Volume 236, Issue 10 (2021)
- Year:
- 2021
- Volume:
- 236
- Issue:
- 10
- Issue Sort Value:
- 2021-0236-0010-0000
- Page Start:
- 6868
- Page End:
- 6883
- Publication Date:
- 2021-02-25
- Subjects:
- ferritinophagy -- gemcitabine sensitivity -- pancreatic ductal adenocarcinomas -- TRIM11 -- UBE2N
Physiology -- Periodicals
Cell physiology -- Periodicals
571.6 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-4652 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/jcp.30346 ↗
- Languages:
- English
- ISSNs:
- 0021-9541
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4955.020000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19606.xml